PLXPQ — PLx Pharma Winddown Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$9.82m
- $8.21m
- 18
- 83
- 11
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.01 | ||
| Price to Tang. Book | 0.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -239.39% | ||
| Return on Equity | -134.26% | ||
| Operating Margin | -1417.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.78 | 0.75 | 0.57 | 0.03 | 8.21 | 3.7 | 3.5 | 233.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PLx Pharma Winddown Corp., formerly PLx Pharma Inc., is a United States-based company. The Company is no longer into any business operations and it has filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code.
Directors
- Michael Valentino CHM (67)
- Natasha Giordano PRE (61)
- Rita O Connor CFO (53)
- Steven Valentino VPR
- Janet Barth VPR
- Gary Balkema IND (66)
- Anthony Bartsh IND (42)
- Kirk Calhoun IND (77)
- Robert Casale IND (62)
- John Hadden IND (51)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- January 14th, 2010
- Public Since
- March 13th, 2014
- No. of Shareholders
- 65
- No. of Employees
- 16
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 29,137,692
- Address
- 9 Fishers Ln Ste E, SPARTA, 07871-2402
- Web
- https://plxpharma.com
- Phone
- +1 7138421249
- Contact
- Lisa Wilson
- Auditors
- Marcum LLP
Upcoming Events for PLXPQ
PLx Pharma Inc Annual Shareholders Meeting
Q3 2023 PLx Pharma Inc Earnings Release
Similar to PLXPQ
12 Retech
Pink Sheets on Nasdaq
1399 Internet Technology Application
Pink Sheets on Nasdaq
3D Pioneer Systems
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
A1
Pink Sheets on Nasdaq
FAQ
What is the PLx Pharma Winddown share price?
As of Today at 01:17 UTC, shares in PLx Pharma Winddown are trading at $0.00. This share price information is delayed by 15 minutes.
How has the PLx Pharma Winddown share price performed this year?
Shares in PLx Pharma Winddown last closed at $0.00 and the price had moved by -99.89% over the past 365 days. In terms of relative price strength the PLx Pharma Winddown share price has underperformed the S&P500 Index by -99.9% over the past year.
What are the analyst and broker recommendations for PLx Pharma Winddown?
The overall consensus recommendation for PLx Pharma Winddown is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PLx Pharma Winddown dividend yield?
PLx Pharma Winddown does not currently pay a dividend.
Does PLx Pharma Winddown pay a dividend?
PLx Pharma Winddown does not currently pay a dividend.
When does PLx Pharma Winddown next pay dividends?
PLx Pharma Winddown does not currently pay a dividend.
How do I buy PLx Pharma Winddown shares?
To buy shares in PLx Pharma Winddown you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PLx Pharma Winddown?
As of the previous close price of $0.00, shares in PLx Pharma Winddown had a market capitalisation of $0.01m.
Where are PLx Pharma Winddown shares listed?
Here are the trading details for PLx Pharma Winddown:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PLXPQ
What kind of share is PLx Pharma Winddown?
Based on an overall assessment of its quality, value and momentum PLx Pharma Winddown is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PLx Pharma Winddown share price forecast for 2023?
The analyst consensus target price for shares in PLx Pharma Winddown is $154.00. That is 5499900% above the last closing price of $0.00.
Analysts covering PLx Pharma Winddown currently have a consensus Earnings Per Share (EPS) forecast of -$1.39 for the next financial year.
Find out moreWhat is the trend in the PLx Pharma Winddown share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PLx Pharma Winddown. Over the past six months, its share price has underperformed the S&P500 Index by -98.9%.
As of the last closing price of $0.00, shares in PLx Pharma Winddown were trading -98.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PLx Pharma Winddown PE Ratio?
The PLx Pharma Winddown PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PLx Pharma Winddown?
PLx Pharma Winddown's management team is headed by:
- Michael Valentino - CHM
- Natasha Giordano - PRE
- Rita O Connor - CFO
- Steven Valentino - VPR
- Janet Barth - VPR
- Gary Balkema - IND
- Anthony Bartsh - IND
- Kirk Calhoun - IND
- Robert Casale - IND
- John Hadden - IND